{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse&page=5", "query": { "condition": "Relapse", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 5306, "total_pages": 531, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T13:04:14.714Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01231919", "title": "MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Leukemias of Ambiguous Lineage", "Acute Myeloid Leukemia/Transient Myeloproliferative Disorder", "Acute Undifferentiated Leukemia", "Aggressive NK-cell Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Intraocular Lymphoma", "Juvenile Myelomonocytic Leukemia", "Mast Cell Leukemia", "Myeloid/NK-cell Acute Leukemia", "Noncutaneous Extranodal Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 45, "start_date": "2011-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231919" }, { "nct_id": "NCT04847453", "title": "Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent AL Amyloidosis", "Refractory AL Amyloidosis" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Transabdominal Ultrasound", "type": "PROCEDURE" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-08-03", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 16, "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04847453" }, { "nct_id": "NCT00002481", "title": "Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "St. Luke's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "1990-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002481" }, { "nct_id": "NCT02763319", "title": "A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Rituximab (RTX)", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Bendamustine (BEN)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2016-11-28", "completion_date": "2024-06-21", "has_results": true, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 18, "location_summary": "Anaheim, California • Bakersfield, California • Burbank, California + 15 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02763319" }, { "nct_id": "NCT02538965", "title": "A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 17, "start_date": "2015-11-19", "completion_date": "2019-01-11", "has_results": true, "last_update_posted_date": "2020-01-07", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538965" }, { "nct_id": "NCT00309907", "title": "Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Disseminated Neuroblastoma", "Juvenile Myelomonocytic Leukemia", "Previously Treated Childhood Rhabdomyosarcoma", "Previously Treated Myelodysplastic Syndromes", "Pulmonary Complications", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "etanercept", "type": "BIOLOGICAL" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 39, "start_date": "2006-04", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-09-29", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Arcadia", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309907" }, { "nct_id": "NCT06304636", "title": "Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma", "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "Descartes-15", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cartesian Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-06-19", "completion_date": "2025-11-13", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06304636" }, { "nct_id": "NCT03797261", "title": "A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Non-Hodgkin's Lymphoma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "AMG 176", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-03-18", "completion_date": "2019-12-30", "has_results": false, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Iowa City, Iowa + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797261" }, { "nct_id": "NCT01132573", "title": "Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "entinostat", "type": "DRUG" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 27, "start_date": "2010-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-07-17", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 4, "location_summary": "Aurora, Colorado • Denver, Colorado • Baltimore, Maryland", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132573" }, { "nct_id": "NCT00312845", "title": "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bortezomib + Rituximab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 676, "start_date": "2006-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-06-25", "last_synced_at": "2026-10-20T13:04:14.714Z", "location_count": 41, "location_summary": "Opelika, Alabama • Alhambra, California • Bakersfield, California + 36 more", "locations": [ { "city": "Opelika", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00312845" } ] }